Re: Re: the article blasting AMPE is working well to help the shorts cover their position before major news hits
by racavalli . 21 minutes ago . Permalink
This is a key question to the current valuation problem the company has had since day 1.
When Ampio's shareholders and management decided to become a publicly traded company, they weighed their options. 1 - do traditional IPO and take a year longer and pay a million or more in the process......or.......buy a shelf company that is already approved for trading and is deemed to be liability free.
To save time and money, they chose to buy a shelf company. That meant that no known bankers EVER had any knowledge of the company. No bankers ..... Except for the questionable and not followed Aegis and Fordham . . . . No coverage . . . . no visibility except for the visibility I brought to the company with my articles that were all true and where everything was substantiated.
The basic simple fact that absolutely cannot be denied is that INVESTORS WILL NOT INVEST TO ANY SIGNIFICANT DEGREE IN ANY STOCK THAT IS NOT FOLLOWED BY MAJOR BANKERS. THAT IS A CARDINAL RULE ON WALL STREET. Look as hard as you can and you will never find any company whose stock did well for any extended period of time that was not covered by major or well known analysts and bankers.
The only bankers the company has ever dealt with are two very tiny, very unknown and very unfollowed firms called Fordham and Aegis.
If you look into this, you will see that there is not one known banker who covers AMPE.
Management says they don't want to pay the high fees.
I undertand, but the big question is ...... was this wise?
I personally do not think so because if they did the traditional IPO path, based on current comps in the marketplace, AMPE shares would be selling at least $20 per share instead of $3.79 and headed much lower.
I have been accused of writing articles to pump the stock which implies there is going to be a dump and somebody will profit. First, there has never been a seller trying to take advantage of my articles and second, my ONLY mission was to share their unusually exciting story with the investment community that knows nothing about them and still doesn't because management doesn't have a clue about how their shares are valued and they certainly does not know how to get their story out. Everytime they issue a press release that is good news, the stock drops. What does that tell you.
I believe this company knows what it is doing with their business and is going to surprise on the upside eventually even in spite of themselves, but I also believe their shares would be much much higher today , , , , and tomorrow, if they only knew how to get out of their own way and talk to shareholders the same way the more successful companies do.
Sentiment: Strong Buy but be patient and average down.
yes . . .you are correct that a search into clincaltrials.gov would reveal any trial in the u.s. and zertane has not been done in the u.s. there was a great deal of uncertainty that the company still has not clarified about macalusos comments from the noble presentation the other day.
in the recent noble presentation, macaluso said that the questionnaire portion of the trial has been done and they are waiting to hear from the fda. once the fda approves it, assuming it is approved and not denied, then their pharma partner, if they are still interested, will take over the phase III trial that will probably go fairly quickly.